Norketotifen is under clinical development by Emergo Therapeutics and currently in Phase I for Chronic Fatigue Syndrome (Myalgic Encephalomyelitis). According to GlobalData, Phase I drugs for Chronic Fatigue Syndrome (Myalgic Encephalomyelitis) does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Norketotifen LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Norketotifen overview
Norketotifen is under development for the treatment of flu and flu-like viral infections ,allergic rhinitis, unspecified influenza virus Infections and influenza like illness, chronic fatigue syndrome (myalgic encephalomyelitis) and coronavirus disease 2019 (COVID-19). The drug candidate is administered as oral capsule. It is the metabolite or byproduct of ketotifen. It acts by targeting histamine H1 receptors.
Emergo Therapeutics overview
Emergo Therapeutics is developing immunomodulator to treat coronavirus disease. The company is headquartered in Durham, North Carolina, the US.
For a complete picture of Norketotifen’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
